Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 976 to 990 of 1001 results for public health medicine & health

  1. FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)

    NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing .

  2. Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy (TA1126)

    Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.

  3. Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (HTG553)

    Evidence-based recommendations on implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke.

  4. MHRA-NICE pathway opens for business – everything you need to know to get started

    Learn how the MHRA and NICE are getting medicines to patients 3 to 6 months sooner by delivering same time decisions on licensing and value.

  5. First treatment for vitiligo recommended by NICE for NHS use, bringing hope to over 80,000 people

    For the first time, NICE has recommended a medicine that effectively treats the underlying cause of devastating skin condition vitiligo

  6. NICE's backing of the prostate cancer drug abiraterone could help thousands and save the NHS millions

    Our landmark review demonstrates a new approach to keeping NHS care up-to-date and could benefit thousands of adults with metastatic prostate cancer.

  7. Shaping the future of global health technology assessment

    Learn about our role in the new international Health Economics Methods Advisory (HEMA) and its ambitions to make a real difference to patients around the world.

  8. First HIV prevention injection for people unable to have daily PrEP recommended

    A ground-breaking HIV-1 prevention injection has been recommended by NICE, marking a significant advance for a small group of adults and young people unable to have daily pre-exposure prophylaxis (PrEP) tablets.

  9. Same time decisions on licensing and value - what pharmaceutical companies need to know

    Learn how NICE and MHRA are launching an aligned pathway to accelerate patient access to medicines and provide a more efficient route for industry.

  10. Biggest shake-up in type 2 diabetes care in a decade announced

    Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority clinical pathways described in the 10-Year Health Plan for the NHS.

  11. New guideline will help cut falls and related hospital admissions for older and at-risk people

    Personalised assessments that consider factors including the hazards in a person’s home, and their previous medical history will help reduce falls in older and at-risk people, according to a new NICE guideline.

  12. NICE describes how weight loss drug tirzepatide will be rolled out

    The medication will initially be offered only to those people with the highest clinical needs.

  13. NICE and NHS England announce plan to enable innovative tech to be adopted quicker

    NHS patients in England will benefit from faster access to the most innovative and cutting-edge medical technologies under new plans.

  14. Working at the forefront of neurodegenerative disease research

    Claire Hawksworth reveals NICE’s role in a global partnership to better understand neurodegenerative conditions and speed up delivery of innovative treatments.

  15. Hundreds of thousands set to benefit from new treatment to prevent heart attacks and strokes

    NICE has published final draft guidance which recommends icosapent ethyl for reducing the risk of heart attacks and strokes in adults who have raised blood fats.